144 related articles for article (PubMed ID: 10195619)
1. A novel immunization method to induce cytotoxic T-lymphocyte responses (CTL) against plasmid-encoded herpes simplex virus type-1 glycoprotein D.
Cruz PE; Khalil PL; Dryden TD; Chiou HC; Fink PS; Berberich SJ; Bigley NJ
Vaccine; 1999 Mar; 17(9-10):1091-9. PubMed ID: 10195619
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of DNA encoding herpes simplex virus type-1 glycoprotein D enhances the cellular response to primary viral challenge.
Rogers JV; Bigley NJ; Chiou HC; Hull BE
Arch Dermatol Res; 2000 Nov; 292(11):542-9. PubMed ID: 11194892
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
4. Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver.
Rogers JV; Hull BE; Fink PS; Chiou HC; Bigley NJ
Vaccine; 2000 Feb; 18(15):1522-30. PubMed ID: 10618550
[TBL] [Abstract][Full Text] [Related]
5. Receptor-mediated gene delivery and expression in vivo.
Wu GY; Wu CH
J Biol Chem; 1988 Oct; 263(29):14621-4. PubMed ID: 3049582
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T lymphocytes. Their relevance in herpesvirus infections.
Martin S; Cantin E; Rouse BT
Ann N Y Acad Sci; 1988; 532():257-72. PubMed ID: 2845846
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor.
Merwin JR; Noell GS; Thomas WL; Chiou HC; DeRome ME; McKee TD; Spitalny GL; Findeis MA
Bioconjug Chem; 1994; 5(6):612-20. PubMed ID: 7873664
[TBL] [Abstract][Full Text] [Related]
8. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.
Wu GY; Wu CH
J Biol Chem; 1987 Apr; 262(10):4429-32. PubMed ID: 3558345
[TBL] [Abstract][Full Text] [Related]
9. Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro.
Wu GY; Wu CH
Biochemistry; 1988 Feb; 27(3):887-92. PubMed ID: 2835080
[TBL] [Abstract][Full Text] [Related]
10. Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.
Rosenthal KL; Smiley JR; South S; Johnson DC
J Virol; 1987 Aug; 61(8):2438-47. PubMed ID: 3037106
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
[TBL] [Abstract][Full Text] [Related]
12. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.
Endresz V; Kari L; Berencsi K; Kari C; Gyulai Z; Jeney C; Pincus S; Rodeck U; Méric C; Plotkin SA; Gönczöl E
Vaccine; 1999 Jan; 17(1):50-8. PubMed ID: 10078607
[TBL] [Abstract][Full Text] [Related]
13. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
15. Cell surface distribution and intracellular fate of asialoglycoproteins: a morphological and biochemical study of isolated rat hepatocytes and monolayer cultures.
Zeitlin PL; Hubbard AL
J Cell Biol; 1982 Mar; 92(3):634-47. PubMed ID: 6282890
[TBL] [Abstract][Full Text] [Related]
16. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis.
Inoue T; Inoue Y; Hayashi K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
Cornea; 2002 Oct; 21(7 Suppl):S79-85. PubMed ID: 12484704
[TBL] [Abstract][Full Text] [Related]
17. Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent.
Cho CW; Cho YS; Lee HK; Yeom YI; Park SN; Yoon DY
Biotechnol Appl Biochem; 2000 Aug; 32(1):21-6. PubMed ID: 10918034
[TBL] [Abstract][Full Text] [Related]
18. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
Martin S; Rouse BT
J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
[TBL] [Abstract][Full Text] [Related]
19. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands.
Eo SK; Lee S; Kumaraguru U; Rouse BT
Vaccine; 2001 Sep; 19(32):4685-93. PubMed ID: 11535317
[TBL] [Abstract][Full Text] [Related]
20. Targeting specificity and pharmacokinetics of asialoorosomucoid, a specific ligand for asialglycoprotein receptor on hepatocyte.
Yang DY; Ouyang CH; Lu FG; Liu XW; Huang LQ
J Dig Dis; 2007 May; 8(2):89-95. PubMed ID: 17532821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
